ArticleInvestigative ophthalmology & visual science2018
Lycium Barbarum Polysaccharides Protect Retina in rd1 Mice During Photoreceptor Degeneration.
Article in Investigative ophthalmology & visual science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Transient functional preservation precedes retinal ganglion cell degeneration following optic nerve crush.IBRO neuroscience reports · 2026Article
- Lycium barbarum polysaccharide as a retinoprotective agent: A meta-analysis of preclinical evidence from rodent models of retinopathy.Neural regeneration research · 2026Article
- A Structurally CharacterizedAntioxidants (Basel, Switzerland) · 2026Article
- Lycium barbarum glycopeptide and luteolin synergistically protect mouse photoreceptors against N-nitroso-N-methylurea-induced degeneration.Neural regeneration research · 2026Article
- MANF improves cognitive function and attenuates neuroinflammation in APP/PS1 transgenic mice through the TLR4/MYD88/NF-κB signaling pathway.Journal of anesthesia and translational medicine · 2025Article
- Diagnostic and Therapeutic Utility of Extracellular Vesicles in Ocular Disease.International journal of molecular sciences · 2025Review
- Lycium barbarum Extract Enhanced Neuroplasticity and Functional Recovery in 5xFAD Mice via Modulating Microglial Status of the Central Nervous System.CNS neuroscience & therapeutics · 2024Article
- Comparison of retinal parameters between rhesus and cynomolgus macaques.Experimental animals · 2024Article
- Zeaxanthin dipalmitate-enriched wolfberry extract improves vision in a mouse model of photoreceptor degeneration.PloS one · 2024Article
- Perspectives of traditional herbal medicines in treating retinitis pigmentosa.Frontiers in medicine · 2024Article
- Qi-Shen-Tang alleviates retinitis pigmentosa by inhibiting ferroptotic features via the NRF2/GPX4 signaling pathway.Heliyon · 2023Article
- Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes.iScience · 2023Article
- Distinct Role ofPharmaceuticals (Basel, Switzerland) · 2023Review
- Defects and asymmetries in the visual pathway of non-human primates with natural strabismus and amblyopia.Zoological research · 2023Article
- Implications of Neural Plasticity in Retinal Prosthesis.Investigative ophthalmology & visual science · 2022Article
- Mesenchymal stem cell-derived extracellular vesicles protect retina in a mouse model of retinitis pigmentosa by anti-inflammation through miR-146a-Nr4a3 axis.Stem cell research & therapy · 2022Article
- Lutein delays photoreceptor degeneration in a mouse model of retinitis pigmentosa.Neural regeneration research · 2022Article
- Neuroinflammation in retinitis pigmentosa: Therapies targeting the innate immune system.Frontiers in immunology · 2022Review
- Luteolin delays photoreceptor degeneration in a mouse model of retinitis pigmentosa.Neural regeneration research · 2021Article
- 2,3,5,6-Tetramethylpyrazine protects retinal photoreceptors against endoplasmic reticulum stress by modulating ATF4-mediated inhibition of PRP aggregation.Journal of molecular medicine (Berlin, Germany) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Purpose: As an active component in wolfberry, lycium barbarum polysaccharides (LBP) are capable of protecting retinal neurons in several animal disease models. Here, we asked whether LBP rescues the retinal morphology and function in rd1 mouse, a photoreceptor fast-degenerating animal model of retinitis pigmentosa, and in particular focused on LBP's effects on the function of retinal ganglion cells (RGCs) during photoreceptor degeneration. Methods: An equal volume of LBP or control vehicle was daily intraperitoneal (i.p.) injected in rd1 mice from postnatal day 4 (P4) to P14, P20, or P24 when photoreceptors completely degenerate. Immunostaining, electroretinogram (ERG), visual behavior tests and multielectrode array (MEA) recordings were assessed to determine the structure and function of the treated retina. Results: LBP treatment greatly promoted photoreceptor survival, enhanced ERG responses, and improved visual behaviors in rd1 mice. MEA data showed that LBP treatment in general decreased the abnormally high spontaneous spiking that occurs in rd1 mice, and increased the percentage of light-responsive RGCs as well as their light-evoked response, light sensitivity, signal-to-noise ratio, and response speed. Interestingly, LBP treatment affected ON and OFF responses differently. Conclusions: LBP improves retinal morphology and function in rd1 mice, and delays the functional decay of RGCs during photoreceptor degeneration. This is the first study that has examined in detail the effects of LBP on RGC responses. Our data suggest that LBP may help extend the effective time window before more invasive RP therapeutic approaches such as retinoprosthesis are applied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.